ATE457988T1 - A2a-adenosin-rezeptor-antagonisten - Google Patents

A2a-adenosin-rezeptor-antagonisten

Info

Publication number: ATE457988T1
Authority: AT; Austria
Prior art keywords: receptor antagonists; adenosine receptor; alkyl; compounds; cns diseases
Prior art date: 2006-06-26

Application number

AT07796492T

Other languages

English (en)

Inventor

Martin C Clasby

Samuel Chackalamannil

Andrew Stamford

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-26

Filing date

2007-06-25

Publication date

2010-03-15

2007-06-25 Application filed by Schering Corp filed Critical Schering Corp

2010-03-15 Application granted granted Critical

2010-03-15 Publication of ATE457988T1 publication Critical patent/ATE457988T1/de

Links

101150051188 Adora2a gene Proteins 0.000 title 1
229940121359 adenosine receptor antagonist Drugs 0.000 title 1
239000000296 purinergic P1 receptor antagonist Substances 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 2
208000015114 central nervous system disease Diseases 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
208000018737 Parkinson disease Diseases 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000001475 halogen functional group Chemical group 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Psychiatry (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT07796492T 2006-06-26 2007-06-25 A2a-adenosin-rezeptor-antagonisten ATE457988T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US81651606P	2006-06-26	2006-06-26
PCT/US2007/014886 WO2008002596A2 (en)	2006-06-26	2007-06-25	Adenosine a2a receptor antagonists

Publications (1)

Publication Number	Publication Date
ATE457988T1 true ATE457988T1 (de)	2010-03-15

Family

ID=38846284

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07796492T ATE457988T1 (de)	2006-06-26	2007-06-25	A2a-adenosin-rezeptor-antagonisten

Country Status (10)

Country	Link
US (1)	US7713985B2 (de)
EP (1)	EP2038285B1 (de)
JP (1)	JP2010509189A (de)
CN (1)	CN101506215A (de)
AT (1)	ATE457988T1 (de)
CA (1)	CA2655987A1 (de)
DE (1)	DE602007004851D1 (de)
ES (1)	ES2339502T3 (de)
MX (1)	MX2009000104A (de)
WO (1)	WO2008002596A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2011513417A (ja)	2008-03-04	2011-04-28	シェーリングコーポレイション	アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
WO2009136578A1 (ja) *	2008-05-09	2009-11-12	パイオニア株式会社	空間映像表示装置
BRPI1009398A2 (pt)	2009-03-13	2016-03-08	Advinus Therapeutics Private Ltd	compostos de pirimidina fundida substituída
TWI548411B (zh)	2009-04-28	2016-09-11	Kyowa Hakko Kirin Co Ltd	Exercise disorder treatment
WO2011060207A1 (en)	2009-11-16	2011-05-19	Schering Corporation	FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
WO2011101861A1 (en)	2010-01-29	2011-08-25	Msn Laboratories Limited	Process for preparation of dpp-iv inhibitors
CN103261202B (zh) *	2010-09-24	2016-01-20	阿迪维纳斯疗法有限公司	作为腺苷受体拮抗剂的稠合三环化合物
AU2013251079B2 (en) *	2012-04-20	2017-03-23	Ucb Pharma S.A.	Methods for treating Parkinson's disease
CN102659620A (zh) *	2012-05-18	2012-09-12	东南大学	2,4-双(三氟甲基)苄肼的合成方法
WO2014101113A1 (en) *	2012-12-28	2014-07-03	Merck Sharp & Dohme Corp.	Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
WO2014101120A1 (en)	2012-12-28	2014-07-03	Merck Sharp & Dohme Corp.	Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
JP2022507734A (ja)	2018-11-20	2022-01-18	メルク・シャープ・アンド・ドーム・コーポレーション	置換アミノトリアゾロピリミジン及びアミノトリアゾロピラジンアデノシン受容体アンタゴニスト、医薬組成物及びそれらの使用
US12414952B2 (en)	2018-11-20	2025-09-16	Merck Sharp & Dohme Llc	Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
JP2022511778A (ja)	2018-11-30	2022-02-01	メルク・シャープ・アンド・ドーム・コーポレーション	アデノシン受容体拮抗薬としての７－、８－及び１０－置換されたアミノトリアゾロキナゾリン誘導体、医薬組成物及びそれらの使用
AR117164A1 (es)	2018-11-30	2021-07-14	Merck Sharp & Dohme	Derivados de amino-triazoloquinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso para el tratamiento de diversos tipos de cáncer
US12398139B2 (en)	2019-03-05	2025-08-26	Centre For Addiction And Mental Health	Modulators of AMPA receptor signaling
US12552799B2 (en)	2020-03-26	2026-02-17	Nxera Pharma Uk Limited	Triazolone compounds
CA3177056A1 (en)	2020-03-26	2021-09-30	Astrazeneca Ab	5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer
WO2021191376A1 (en)	2020-03-26	2021-09-30	Astrazeneca Ab	Triazolone compounds
WO2021191378A1 (en)	2020-03-26	2021-09-30	Astrazeneca Ab	5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5955465A (en)	1996-03-22	1999-09-21	Neurogen Corporation	1,2,4-triazolo 4,3-c!quinazolin-3-ones and 1,2,4-triazolo 4,3-c!quinazolin-3-thiones
WO2004058974A1 (en)	2002-12-27	2004-07-15	Actar Ab	A method of drug screening to select agonists or antagonists of g protein coupled receptors (gpcr).
US7452892B2 (en)	2005-06-17	2008-11-18	Bristol-Myers Squibb Company	Triazolopyrimidine cannabinoid receptor 1 antagonists
AR057817A1 (es)	2005-09-19	2007-12-19	Schering Corp	Antagonistas del receptor a2a de 2-heteroaril-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidin adenosina. composiciones farmaceuticas

2007
- 2007-06-25 EP EP07796492A patent/EP2038285B1/de active Active
- 2007-06-25 MX MX2009000104A patent/MX2009000104A/es active IP Right Grant
- 2007-06-25 JP JP2009518245A patent/JP2010509189A/ja not_active Withdrawn
- 2007-06-25 AT AT07796492T patent/ATE457988T1/de not_active IP Right Cessation
- 2007-06-25 CN CNA2007800313042A patent/CN101506215A/zh active Pending
- 2007-06-25 WO PCT/US2007/014886 patent/WO2008002596A2/en not_active Ceased
- 2007-06-25 CA CA002655987A patent/CA2655987A1/en not_active Abandoned
- 2007-06-25 US US11/767,624 patent/US7713985B2/en active Active
- 2007-06-25 ES ES07796492T patent/ES2339502T3/es active Active
- 2007-06-25 DE DE602007004851T patent/DE602007004851D1/de active Active

Also Published As

Publication number	Publication date
ES2339502T3 (es)	2010-05-20
EP2038285A2 (de)	2009-03-25
WO2008002596A3 (en)	2008-07-03
EP2038285B1 (de)	2010-02-17
MX2009000104A (es)	2009-01-23
WO2008002596A2 (en)	2008-01-03
US20080255156A1 (en)	2008-10-16
US7713985B2 (en)	2010-05-11
CA2655987A1 (en)	2008-01-03
CN101506215A (zh)	2009-08-12
DE602007004851D1 (de)	2010-04-01
JP2010509189A (ja)	2010-03-25

Legal Events

Date	Code	Title	Description
2010-08-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE602007004851D1 (de)	2010-04-01	A2a-adenosin-rezeptor-antagonisten
TW200726765A (en)	2007-07-16	Triazolopyridine cannabinoid receptor 1 antagonists
TNSN07164A1 (en)	2008-11-21	Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
MX340965B (es)	2016-08-02	Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
GEP20115174B (en)	2011-03-10	Triazolopyrazine derivatives useful as anti-cancer agents
GEP20084551B (en)	2008-11-25	4-phenylamino-quinazolin-6-yl-amides
IL176110A0 (en)	2006-10-05	Azabicyclic heterocycles as cannabinoid receptor modulators
PH12012501122A1 (en)	2012-10-29	Pteridinones as inhibitors of polo-like kinase
MX2009004900A (es)	2009-05-19	Arilamidas sustituidas por tiazol u oxazol.
NO20084853L (no)	2009-02-02	Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
MX2012004848A (es)	2012-05-29	Compuestos heterociclicos triciclicos.
MY169274A (en)	2019-03-21	Fused, tricyclic sulfonamide inhibitors of gamma secretase
MX2010001020A (es)	2010-03-01	Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
MX2009009238A (es)	2009-09-08	Nuevos inhibidores de fosfodiesterasa.
PL1891029T3 (pl)	2010-06-30	Związki organiczne do leczenia stanów zapalnych lub alergicznych
MX2010006230A (es)	2010-06-23	Derivados de arilamida substituidos con triazol y su uso como antagonistas de receptor purinergico p2x3 y/o p2x2/3.
UA92670C2 (ru)	2010-11-25	Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
MX2010002938A (es)	2010-04-01	Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
MX2009011059A (es)	2009-11-26	Aminopirimidinas utiles como inhibidores de cinasas.
MA28706B1 (fr)	2007-06-01	Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
TW200719886A (en)	2007-06-01	Dihydrobenzofuran derivatives and uses thereof
DE602007001463D1 (de)	2009-08-13	Pyrimidin-, chinazolin-, pteridin- und triazinderivate
TW200637863A (en)	2006-11-01	Organic compounds
ATE446089T1 (de)	2009-11-15	2-benzoyl-imidazopyridin-derivate, herstellungsverfahren und ihre verwendung für therapeutika
MX2007013624A (es)	2008-02-12	Inhibidores de proteina cinasa.